MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells

被引:52
作者
Chen, Yan [1 ,3 ]
Feng, Fan [2 ]
Gao, Xudong [1 ]
Wang, Chunping [1 ]
Sun, Huiwei [1 ]
Zhang, Cuihong [1 ]
Zeng, Zhen [1 ]
Lu, Yinying [1 ]
An, Linjing [1 ]
Qu, Jianhui [1 ]
Wang, Fusheng [3 ]
Yang, Yongping [1 ]
机构
[1] Med Sch Chinese PLA, Beijing Hosp 302, Ctr Therapeut Res Hepatocellular Carcinoma, Beijing 100039, Peoples R China
[2] Gen Hosp Shenyang Mil Command, Dept Pharm, Shenyang 110016, Peoples R China
[3] Med Sch Chinese PLA, Beijing Hosp 302, Inst Translat Hepatol, Res Ctr Biol Therapy, Beijing 100039, Peoples R China
关键词
Etoposide; HCC cells; miR-153; PTEN; paclitaxel; sorafenib; LINE-1 ORF-1P FUNCTIONS; HEPATOCELLULAR-CARCINOMA; TRASTUZUMAB RESISTANCE; CANCER; PROMOTES; PROLIFERATION; PROGRESSION; ACTIVATION; TARGETS; AKT;
D O I
10.2174/1568009615666150225122635
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNA-153 (miR-153) is considered to be a tumor regulator. Silencing of miR-153 expression induced apoptosis in breast cancer cells. Data on mechanism suggest that up-regulation of miR-153 level promotes cell proliferation via the down regulation of the expression of PTEN or FOXO1, which attenuates the proliferation of cancerous cells. This study aims to identify the effect of miR-153 on the activity of chemotherapeutic and targeted agents in HCC cells and to investigate the mechanisms involved. MTT, soft agar, trans-well and flow cytometry assays were performed to examine whether miR-153 down-regulated the activity of the chemotherapeutic and targeted drugs, Sorafenib, Etoposide and Paclitaxel in HCC cells. The rate of proliferation inhibition, relative survival rates and IC50 values of each drug were calculated. Western blot and luciferase assays were performed to assess whether miR-153 modulates the expression of important genes related to cell proliferation, apoptosis or survival. Results showed that miR-153 attenuated the effect of Etoposide, Paclitaxel and Sorafenib on HepG2 cells; the IC50 value increased from 0.25 +/- 0.01 mu mol/L to 1.02 +/- 0.14 mu mol/L, 0.05 +/- 0.01 mu mol/L to 0.14 +/- 0.02 mu mol/L and from 1.09 +/- 0.15 mu mol/L to 5.18 +/- 0.99 mu mol/L, respectively. In addition, miR-153 also reduced the effect of these drugs on MHCC-97H, MHCC-97 L and L-02 cells; and it also reduced the effects of Sorafenib, Etoposide and Paclitaxel on anchorindependent growth of HepG2 cells. Over-expression of miR-153 down-regulated the activity of Etoposide and Paclitaxel on cell cycle arrest of HepG2 cells and the effect of Sorafenib on the invasion and migration of HepG2 cells. Furthermore, overexpression of miR-153 also enhanced the growth of HepG2, MHCC-97H, MHCC-97 L and L-02 cells. Mechanisms data showed that overexpression of miR-153 down regulated the activity of luciferase reporters, p15-Luc and p21-Luc; and enhanced the protein level of pro-survival or anti-apoptosis proteins Survivin and BCL-2. These results show that overexpression of miR-153 protects HepG2 cells against the effects of these drugs via multiple mechanisms, and miR-153 may be a novel target for HCC in future diagnostic and therapeutic interventions.
引用
收藏
页码:176 / 187
页数:12
相关论文
共 46 条
  • [31] Parpart Sonya, 2013, Curr Pathobiol Rep, V1, P71
  • [32] On the road to reading the RNA-interference code
    Siomi, Haruhiko
    Siomi, Mikiko C.
    [J]. NATURE, 2009, 457 (7228) : 396 - 404
  • [33] MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells
    Tsai, Pai-Chi
    Bake, Shameena
    Balaraman, Sridevi
    Rawlings, Jeremy
    Holgate, Rhonda R.
    Dubois, Dustin
    Miranda, Rajesh C.
    [J]. BIOLOGY OPEN, 2014, 3 (08): : 741 - 758
  • [34] Multicenter Randomized Controlled Trial of Percutaneous Cryoablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma
    Wang, Chunping
    Wang, Huaming
    Yang, Wuwei
    Hu, Kaiwen
    Xie, Hui
    Hu, Ke-Qin
    Bai, Wenlin
    Dong, Zheng
    Lu, Yinying
    Zeng, Zhen
    Lou, Min
    Wang, Hong
    Gao, Xudong
    Chang, Xiujuan
    An, Linjing
    Qu, Jianhui
    Li, Jin
    Yang, Yongping
    [J]. HEPATOLOGY, 2015, 61 (05) : 1579 - 1590
  • [35] Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
    Wu, Ziqing
    He, Benfu
    He, Jincan
    Mao, Xiangming
    [J]. PROSTATE, 2013, 73 (06) : 596 - 604
  • [36] Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines
    Xu, Jianzhen
    Liao, Xuemei
    Lu, Na
    Liu, Wenming
    Wong, Chi-Wai
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (10) : 2527 - 2531
  • [37] MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment
    Yang, Fan
    Li, Qing-jun
    Gong, Zhen-bin
    Zhou, Liang
    You, Nan
    Wang, Su
    Li, Xiao-lei
    Li, Jun-jie
    An, Jia-ze
    Wang, De-sheng
    He, Yong
    Dou, Ke-feng
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2014, 13 (01) : 77 - 86
  • [38] SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway
    Yang, Peng
    Wang, Gang
    Huo, Hongjun
    Li, Qiang
    Zhao, Yan
    Liu, Yuanhang
    [J]. MEDICAL ONCOLOGY, 2015, 32 (01)
  • [39] LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell
    Yang, Qian
    Feng, Fan
    Zhang, Fan
    Wang, Chunping
    Lu, Yinying
    Gao, Xudong
    Zhu, Yunfeng
    Yang, Yongping
    [J]. CELLULAR SIGNALLING, 2013, 25 (12) : 2652 - 2660
  • [40] High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma
    Yang, Yong-Ping
    Qu, Jian-Hui
    Chang, Xiu-Juan
    Lu, Yin-Ying
    Bai, Wen-Lin
    Dong, Zheng
    Wang, Hong
    An, Lin-Jing
    Xu, Zhong-Xian
    Wang, Chun-Ping
    Zeng, Zhen
    Hu, Ke-Qin
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11